Sarclisa under FDA priority review as first-line myeloma therapy
The U.S. Food and Drug Administration (FDA) has granted…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Bortezomib dosing once a week safer than twice a week: Study
Once-weekly induction therapy with bortezomib is as efficient as…
CAR T-cell therapy anito-cel set for Phase 3 trial in multiple myeloma
Arcellx and Kite Pharma are…
CAR T-cell therapy NXC-201 given orphan drug status in EU
NXC-201, an investigational CAR T-cell therapy, has been designated…
15th annual International Myeloma Foundation gala raises over $675K
At its 15th annual gala, held in New York…
FDA committee votes 12-0 for myeloma trial outcome measure
A unanimous vote by a committee of the U.S.
